Retra Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.40 Cr
as on 08-12-2024
- Paid Up Capital ₹ 1.40 Cr
as on 08-12-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 M
as on 08-12-2024
- Satisfied Charges ₹ 1.70 Cr
as on 08-12-2024
- Revenue -12.13%
(FY 2022)
- Profit 77.52%
(FY 2022)
- Ebitda -6.76%
(FY 2022)
- Net Worth 15.60%
(FY 2022)
- Total Assets -26.01%
(FY 2022)
About Retra Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.40 Cr and a paid-up capital of Rs 1.40 Cr.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹1.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pinjiwakkam Subramanyam, Periganji Ishwarya, Ganiga Manjunatha, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239KA2019PTC128286
- Company No.
128286
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Sep 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Retra Life Sciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pinjiwakkam Subramanyam  | Director | 25-Sep-2019 | Current |
| Periganji Ishwarya | Additional Director | 10-Nov-2022 | Current |
| Ganiga Manjunatha | Additional Director | 10-Nov-2022 | Current |
| Mamatha Patil | Director | 31-Mar-2022 | Current |
| Shobha Venkatesh | Director | 25-Sep-2019 | Current |
Financial Performance of Retra Life Sciences.
Retra Life Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 12.13% decrease. The company also saw a substantial improvement in profitability, with a 77.52% increase in profit. The company's net worth Soared by an impressive increase of 15.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Retra Life Sciences?
In 2021, Retra Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 06 Nov 2023 | ₹5.00 M | Open |
Others Creation Date: 17 Aug 2021 | ₹1.70 Cr | Satisfied |
How Many Employees Work at Retra Life Sciences?
Unlock and access historical data on people associated with Retra Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Retra Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Retra Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
